Copyright
©The Author(s) 2015.
World J Gastroenterol. Jun 28, 2015; 21(24): 7343-7348
Published online Jun 28, 2015. doi: 10.3748/wjg.v21.i24.7343
Published online Jun 28, 2015. doi: 10.3748/wjg.v21.i24.7343
Timing, intervention | Treatment arms (n) | Results | |
INT0116[4]United States | Adjuvant, chemoradiation | Surgery alone (n = 275) | Median OS: 27 moHR = 1.35, 95%CI: 1.09-1.66 (P = 0.005) |
Surgery + 5-FU/LV/RT (n = 281) | Median OS: 36 mo | ||
ARTIST[6] | Adjuvant, chemoradiation | Surgery (D2 resection) + capecitabine/cisplatin (n = 228) | 3-yr DFS: 74.2% |
South Korea | Surgery (D2 resection) + capecitabine/cisplatin/RT (n = 230) | 3-yr DFS: 78.2% | |
(P = 0.08) | |||
ARTIST II[28] | Adjuvant, chemoradiation | Surgery (D2 resection, node-positive only) + capecitabine/cisplatin | In progress |
South Korea | Surgery (D2 resection, node-positive only) + capecitabine/cisplatin/RT | ||
ACTS-GC[9] | Adjuvant, chemotherapy | Surgery alone (D2 resection) (n = 30) | 5-yr OS: 61.1% |
Japan | Surgery (D2 resection) + oral S-1 postop (n = 529) | 5-yr OS: 71.7HR = 0.67, 95%CI: 0.54-0.83 | |
CLASSIC[8] | Adjuvant, chemotherapy | Surgery alone (D2 resection) (n = 515) | 3-yr DFS: 59% (53%-64%) |
South Korea | Surgery (D2 resection) + 8 cycles oral capecitabine + IV oxaliplatin (n = 520) | 3-yr DFS: 74% (69%-79%)HR = 0.56, 95%CI: 0.44-0.72 (P < 0.0001) | |
MAGIC[10] | Perioperative, chemotherapy | Surgery alone (n = 253) | 5-yr OS: 23% |
United Kingdom | 3 cycles ECF preop + surgery + 3 cycles ECF postop (n = 250) | 5-yr OS: 36%HR = 0.75, 95%CI: 0.60-0.93 (P = 0.009) | |
FNCLCC/FFCD[11] | Perioperative, chemotherapy | Surgery alone (n = 111) | 5-yr OS: 24% |
France | 5-FU/cisplatin preop + surgery + 5-FU/cisplatin postop (n = 113) | 5-yr OS: 38%HR = 0.69, 95%CI: 0.50-0.95 (P = 0.02) | |
POET[15] | Neoadjuvant, chemoradiation | 2.5 cycles PLF preop + surgery (n = 59) | 3-yr OS: 27.7% |
Germany | 2 cycles PLF then PLF/RT preop + surgery (n = 60) | 3-yr OS: 47.4%HR = 0.67, 95%CI: 0.41-1.07 (P = 0.07) | |
CRITICS[7] | Perioperative, combination | 3 cycles ECX/EOX preop + surgery + capecitabine/cisplatin/RT postop | In progress |
The Netherlands | 3 cycles ECX/EOX preop + surgery + 3 cycles ECX/EOX postop | ||
TOPGEAR[12] | Perioperative, combination | 3 cycles ECF preop + surgery + 3 cycles ECF postop | In progress |
Australia/New Zealand/Europe/Canada | 2 cycles ECF with 5-FU/RT preop + surgery + 3 cycles ECF postop | ||
Neo-AEGIS[13] | Perioperative, combination | 3 cycles ECF preop + surgery + 3 cycles ECF postop | In progress |
Ireland | Carboplatin/paclitaxel/RT preop + surgery | ||
MAGIC-B[22]United Kingdom | Perioperative, chemotherapy | 3 cycles ECX preop + surgery + 3 cycles ECX postop | In progress |
3 cycles ECX with lapatinib or bevacizumab preop + surgery + 3 cycles ECX with lapatinib or bevacizumab postop |
- Citation: Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol 2015; 21(24): 7343-7348
- URL: https://www.wjgnet.com/1007-9327/full/v21/i24/7343.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i24.7343